
Commentary|Podcasts|November 18, 2025
Inside AHA’s Late-Breaking Lipid Trials: The Rise of Oral PCSK9 Inhibition
Fact checked by: Ron Panarotti
Advertisement
This week, host Craig Beavers spoke with Joe Saseen, PharmD, BCPS, BCACP, CLS, about several key trials presented at the American Heart Association 2025 Scientific Sessions.
Show notes:
- VESALIUS-CV trial:
https://www.nejm.org/doi/full/10.1056/NEJMoa2514428 CORAL REEF trial
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists at the Forefront: Initiating, Monitoring, and Identifying Candidates for VMAT2 Therapy
2
Up to 5 Cups of Coffee Daily Safe—and Benficial—for Most Adults
3
FDA Accepts NDA for AD109 for Treatment of Adults With Obstructive Sleep Apnea
4
Could VER-01 Redefine the Role of Cannabis in Chronic Pain Care?
5





































































































